Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They fit together perfectly, Paul may want to join the business ethics class too:
https://casetext.com/case/lepine-v-rosenbaum?__cf_chl_jschl_tk__=1280e6e2bff02a9131d5f949eb08918be37bf8ff-1626338545-0-AXgBAJnZP-h4JU8FfjTMNd3ie35qTFkwLsQ1v73RHpLn5USnt_ej6i2Yt5JZky49-MPk_a0P5f6jzPJhr_Ek3zNYCxerO_lG7UzkNKCWab8c9i7WIQ-vTGgsP4uuUPJSwYwW0SceXLSxFqXC3UH-NHYZHD15HVt9_vCWpWtRvlNlDwH9wgQa_DrjXPExrGFFWOmWgM0QfRfTEAOpxWAlxA0UUm6LiolYRUK2VpsgREbB9oLjtkw-RiYJwiGy3nh_8QLgZa59i5RbfpmWQepcu4YA-yXJI4OxkeJ1tfFWJ__sBzGkMuHrs4TM4nE5jVG8zpPrSec3b-dpHWsjIZRnbjS9aJfPe30F5eB1tbDGMDVFa7HjyKn_UYFUEnBpoxjn4teORHYxfyR5fLHUtqq84DAOYSKCfjK0-7CF4rPXDGLKQbInRmCdjOt0mHPy4XrZj84SUhIznqgRf8B9kZxMbPKQzxiRrA0aLtJvXxSlvRtl
Quote:
"Well, except that is not quite the case. The science for HIV treatment is good by most accounts, the subbrackets in the Covid test, under 50 was statistically significant."
Brazil trials will pan out nicely without the ridiculous 2 dosage restriction.
Former CEO Caracciolo is responsible for the acquisition of Prostagene. Both Caracciolo and Pestell are now 13d members.
VANCOUVER, Washington, Nov. 19, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces that on Friday November 16, 2018 it completed the previously announced acquisition of privately held ProstaGene, LLC. Concurrently, Richard G. Pestell, M.D., Ph.D., M.B.A., F.A.C.P., F.R.A.C.P., founder and former Chief Executive Officer of ProstaGene, has been appointed to the CytoDyn board of directors and named Chief Medical Officer with responsibility for leading all PRO 140 (leronlimab) programs in non-HIV indications. Dr. Pestell has served as the Company’s Interim Chief Medical Officer since August 2018.
“Richard is a driving force in CCR5 antagonist research and we gain significant expertise and intellectual property with this acquisition that advances the development of PRO 140 as a novel cancer metastasis therapeutic,” said Anthony D. Caracciolo, CytoDyn’s Chairman. “We are privileged to have Richard join CytoDyn to expand our executive and scientific team, and we enthusiastically welcome him as the newest member of our board of directors.”
Under the terms of the definitive agreement, CytoDyn acquired substantially all of the assets of ProstaGene, including the transfer or assignment of certain intellectual property rights held by ProstaGene and Dr. Pestell. The aggregate transaction consideration consisted of 27,000,000 shares of CytoDyn common stock.
https://www.cytodyn.com/newsroom/press-releases/detail/299/cytodyn-completes-acquisition-of-prostagene-and-names-dr
It's said he already had received both shots:
This is what I got. pic.twitter.com/N0ofAaZJQs
— Environmentalist (@in_environ) May 3, 2021
Here is also something to chew on:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160804180
It's been proposed that neuropilin-1 is a secondary receptor for COVID-19. With neuropilin-1 downregulating platelet-derived growth factor receptor signalling there may be a connection. If there is a connection leronlimab may help since it downregulates neuropilin-1.
https://childrenshealthdefense.org/defender/pfizer-moderna-vaccines-life-threatening-blood-disorder/
Up to 100 UK children a week hospitalised with rare post-Covid disease
https://www.theguardian.com/world/2021/feb/05/up-to-100-uk-children-a-week-hospitalised-with-rare-post-covid-disease
Interesting times ahead...
Not so good for hedge funds and naked shorts though. They are finally being exposed.
Sent this post to CyDy.
I hope CyDy lawyers will read these lies and take action.
Calling CD10 a "failure" displays the general lack of understanding of a phase 2 trial.
I will go over to the Wolfson family office and ask as long as it's still around. They might have had an impact on the hospitalized death rate, so it would make sense to get first hand information.
Wataboutdat?
Why is 21st of January suddenly being promoted in such excessive ways? I could come up with answers...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160804180
Exactly, it's also the engineers behind Elon Musk who receive all the praise.
That statement is pure gold.
Not sure BP will agree, expect heavy opposition.
Yes everyone is laughing.
Cytodyn is shining bright despite all efforts to spread misinformation.
https://www.ynetnews.com/health_science/article/SJvLIxRnw
For first time in Israel, man dies in second COVID-19 infection...
There is never black or white, just shades of grey.
https://investorshub.advfn.com/boards/replies.aspx?msg=160118599
Britain advises people with allergy history to avoid Pfizer vaccine
https://de.reuters.com/article/health-coronavirus-britain-vaccine-nhs/britain-advises-people-with-allergy-history-to-avoid-pfizer-vaccine-idUSKBN28J1GD
https://www.bbc.com/news/health-55244122
And of course Cytodyn's marketcap isn't just based on multiple indications (not just Covid19, also HIV and others), but also it is now about to finish its Phase 3 (not as you stated "PH2 CV").
https://www.cytodyn.com/newsroom/press-releases/detail/487/cytodyn-reaches-enrollment-target-of-293-patients-for-2nd
At Cytodyn Covid19 is just one of many indications, so the market cap comparison is skewed.
It's obviously painful to have missed ones re-entry moment. What is ridiculous for some fortunately isn't for everyone. Otherwise the world would still be considered to be flat.
https://www.pfizer.com/clinicalprotocol
I'm not sure I'm reading it correctly, but maybe Pfizer/Biontech also takes asymptomatic cases into efficacy consideration?
Page 55, Chapter 8.1:
"In addition, a serological definition will be used for participants without clinical presentation of COVID-19:
• Confirmed seroconversion to SARS-CoV-2 without confirmed COVID-19: positive N-binding antibody result in a participant with a prior negative N-binding antibody
result
Serum samples will be obtained for immunogenicity testing at the visits specified in the SoA.
The following assays will be performed:
• SARS-CoV-2 neutralization assay
• S1-binding IgG level assay
• RBD-binding IgG level assay
• N-binding antibody assay"
What if that run to 10$ and the immediate sell orders were just stock manipulation. If we would cut that out and the SP remained in this 2,xx - 3,xx$ region?
Just curious. What would the TA say then?
He surely had enough time to go golfing.
6 months ago not too many knew about Leronlimab. It was his duty to create a special task force in order to accumulate knowledge about cures & vaccines. Again, he was playing golf. In the meantime 250,000 deaths in the US and the number is sharply rising.
If Trump had the mental capacity he would have pushed Leronlimab over the finish line in order to save himself.
Instead 6 months ago he was sitting with the Gilead CEO giving a press conference about the Ramitsevere approval.
Actually divisions by zero mathematically strive towards infinity. So that's the SP CyDy is heading to...
BP cannot put as much money to anyone's pocket as they are about to lose soon.
What "they" could offer are merely peanuts.
NP's ego is too big for those kind of games, he wants to hit the real jackpot. That's the advantage of having someone with his background.
https://charleshughsmith.blogspot.com/2020/11/vaccines-too-little-too-late.html?
This is the original link^
Lots of rumours & guessing, we need more armchair CEOs.
Good find, thanks a lot.
The long time side effects (for example after a few years) unfortunately will remain unknown for now.
BP won't be made accountable for that.
This must be investigation number 595. Like the rest, completely pointless. Might scare off a few daytraders though :D
Old news and Form 4 not needed.
Hello Sir,
here is one more thing ohm20 wrote about the BLA process some time ago:
"This just goes to show the bias that exists against Cytodyn.
Quote:
2. Is not necessarily a final decision regarding the scientific/medical merits of the application; instead, it is an early signal to the applicant that the application has omissions or inadequacies so severe as to render the application incomplete on its face or to introduce significant impediments to a prompt and meaningful review (e.g., the need for substantial amounts of additional data and analyses). This message is transmitted early so that "repairs" can be promptly initiated by the applicant.
The FDA initially said they wanted the 700mg dose and the only thing they needed was more safety data from that dosage. That was done by January. At that point they asked for all data from the monotherapy trial. That data would have little to no relevance to the combination trial because it would simply muddy the waters of what leronlimab does in combination with other drugs. Then they ask for data from the completed monotherapy trial.
Once the safety data was submitted there were no omissions or inadequacies. Adding data from a second trial would introduce significant impediments for the FDA to make a determination.
Quote:
May apply if the application contains other uncorrected deficiencies (e.g., manufacturing or product specifications) which were clearly communicated to the applicant before submission of the application sufficient to require resolution before a meaningful review could occur.
There have been no call outs by the FDA in regard to manufacturing and the information about the injectable kit was included in the BLA.
In other words the FDA is corrupt."
Hello Sir,
please don't believe stories being told by some with questionable agendas. And once again thank you for sharing your experience, knowledge & big picture.
Ohm (who probably knows more than anyone) wrote the following about our Nasdaq and BLA process, and he absolutely nailed it:
"Almost a year ago I pointed out that one of the things that was needed for NASDAQ was either money on hand to cover a year of expenses or a credible business plan that would show how revenues would achieve that. We either borrow a large amount of money and put the intellectual property at risk, a share offering at a low stock price or wait for approval and it gets covered. There was probably an expectation of approval on mild/moderate which was dashed by the overwhelming amount of mild and asymptomatic patients.
Quote:
Second, the BLA for the FDA sounded like Cytodyn was poorly prepared .
How would Cytodyn have the foreknowledge to prepare for the FDA asking for more and more data. They certainly couldn't have foreseen the FDA asking for data that didn't even exist yet.
This particular trope is hammered on continuously as another mistake by Nader. Just another factual inaccuracy to fulfill whatever agenda they have."
Some obviously are new to pre-revenue bio tech sector.